Hepion Pharmaceuticals, Inc. (HEPA)

Market Cap	464.81K -74.1%
Revenue (ttm)	n/a
Net Income	-9.17M
EPS	-1.41
Shares Out	11.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,340
Average Volume	8,080
Open	0.0410
Previous Close	0.0410
Day's Range	0.0400 - 0.0434
52-Week Range	0.0330 - 7.8000
Beta	2.00
RSI	44.33
Earnings Date	Mar 27, 2026

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The compan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 22
• Stock Exchange: OTCMKTS
• Ticker Symbol: HEPA